Pasar al contenido principal

ESTUDIO DEL PAPEL DEL RECEPTOR DE CANNABINOIDES CB1 EN ASTROGLIA Y DEL RECEPTOR VANILOIDE TRPV1 EN NEURONAS Y ASTROCITOS EN UN MODELO DE EPILEPSIA DEL LOBULO TEMPORAL

SAF2015-65034-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario UNIVERSIDAD DEL PAIS VASCO EUSKAL HERRIKO UNIBERTSITATEA
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Role of the endocannabinoid system in drug addiction

  • Manzanares, Jorge
  • Cabañero Ferri, David
  • Puente, Nagore
  • García-Gutiérrez, María S.
  • Grandes, Pedro
  • Maldonado, Rafael, 1961-
Drug addiction is a chronic relapsing disorder that produces a dramaticglobal health burden worldwide. Not effective treatment of drug addiction is currently available probably due to the difficulties to find an appropriate target to manage this complex disease raising the needs for further identification of novel therapeutic approaches. The endocannabinoid system has been found to play a crucial role in the neurobiological substrate underlying drug addiction. Endocannabinoids and cannabinoid receptors are widely expressed in the main areas of the mesocorticolimbic system that participate in the initiation and maintenance of drug consumption and in the development of compulsion and loss of behavioral control occurring during drug addiction. The identification of the important role played by CB1 cannabinoid receptors in drug addiction encouraged the possible used of an early commercialized CB1 receptor antagonist for treating drug addiction. However, the incidence of serious psychiatric adverse events leaded to the sudden withdrawal from the market of this CB1 antagonist and all the research programs developed by pharmaceutical companies to obtain new CB1 antagonists were stopped. Currently, new research strategies are under development to target the endocannabinoid system for drug addiction avoiding these side effects, which include allosteric negative modulators of CB1 receptors and compounds targeting CB2 receptors. Recent studies showing the potential role of CB2 receptors in the addictive properties of different drugs of abuse have open a promising research opportunity to develop novel possible therapeutic approaches., We acknowledge the financial support of the Spanish MINECO (#SAF2017-84060-R-AEI/FEDER-UE), Instituto de Salud Carlos III-RETICS(##RD16/0017/0020), Ministerio de Sanidad, Servicios Sociales e Igualdad-Plan Nacional Sobre Drogas (#PNSD-2017I068), and the Generalitat de Catalunya-AGAUR ((#2017-SGR-669 and #ICREA Acadèmia2015) and the European Commission-DG RTD (#FP7-HEALTH-F2-2013-602891-NeuroPain) to RM. FEDER funding support is also acknowledged. This work was supported by Red de Trastornos Adictivos, Instituto de Salud Carlos III (ISC-III) and European Regional Development Funds-European Union (ERDF-EU) (RD16/0017/0012), The Basque Government (BCG IT764-13) and MINECO/FEDER, UE(SAF2015-65034-R) to PG. This research was supported by Instituto de Salud Carlos III (RETICS, RD12/0028/0019, RD16/0017/0014 and RD06/0001/1004), Plan Nacional Sobre Drogas (PNSD 2016/016 and 2007/061), Ministerio de Economía y Competitividad (FIS, PI14/00438) and Ministerio de Ciencia e Innovación (SAF2008-01106) to JM
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

2-Arachidonoylglycerol Reduces Proteoglycans and Enhances Remyelination in a Progressive Model of Demyelination

  • Feliú, Ana
  • Bonilla del Río, Itziar
  • Carrillo-Salinas, F. J.
  • Hernández-Torres, Gloria
  • Puente, Nagore
  • Ortega-Gutiérrez, S.
  • López-Rodríguez, María L.
  • Grandes, Pedro
  • Mecha, Miriam
  • Guaza, Carmen
The failure to undergo remyelination is a critical impediment to recovery in multiple sclerosis. Chondroitin sulfate proteoglycans (CSPGs) accumulate at demyelinating lesions creating a nonpermissive environment that impairs axon regeneration and remyelination. Here, we reveal a new role for 2-arachidonoylglycerol (2-AG), the major CNS endocannabinoid, in the modulation of CSPGs deposition in a progressive model of multiple sclerosis, the Theiler's murine encephalomyelitis virus-induced demyelinating disease. Treatment with a potent reversible inhibitor of the enzyme monoacylglycerol lipase, which accounts for 85% of the 2-AG degradation in the mouse CNS, modulates neuroinflammation and reduces CSPGs accumulation and astrogliosis around demyelinated lesions in the spinal cord of Theiler's murine encephalomyelitis virus-infected mice. Inhibition of 2-AG hydrolysis augments the number of mature oligodendrocytes and increases MBP, leading to remyelination and functional recovery of mice. Our findings establish a mechanism for 2-AG promotion of remyelination with implications in axonal repair in CNS demyelinating pathologies., This work was supported by Ministry of the Economy and Competition (MINECO) Grants SAF2013-42784-R and SAF2016-76449-R, Comunidad de Madrid Grant S2011/BMD-2308, and Red Española de Esclerosis Múltiple Grants RD12/0032/0008 and RD16/0015/0021 (sponsored by the Fondo de Investigación Sanitaria) to C.G., Basque Government Grant IT764-13, MINECO/FEDER Grant SAF2015-65034-R, and University of the Basque Country Grant UPV/EHU UFI11/41 to P.G., and MINECO Grant SAF2013-48271-C2-1-R to M.L.-R. None of the funding bodies played any role in the study design, data collection and analysis, the decision to publish, or the preparation of the manuscript. A.F. is a predoctoral fellow supported by MINECO Grant BES-2014-068459. We thank Laura Ramos for excellent technical support., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Glucose metabolism links astroglial mitochondria to cannabinoid effects

  • Jimenez-Blasco, Daniel
  • Busquets-Garcia, Arnau
  • Hebert-Chatelain, Etienne
  • Serrat, Roman
  • Vicente-Gutiérrez, Carlos
  • Ioannidou, Christina
  • Gómez-Sotres, Paula
  • López-Fabuel, Irene
  • Resch-Beusher, Monica
  • Resel, Eva
  • Arnouil, Dorian
  • Saraswat, Dave
  • Varilh, Marjorie
  • Cannich, Astrid
  • Julio-Kalajzic, Francisca
  • Bonilla-Del Río, Itziar
  • Almeida, Angeles
  • Puente, Nagore
  • Achicallende, Svein
  • López-Rodríguez, María L.
  • Jollé, Charlotte
  • Déglon, Nicole
  • Pellerin, Luc
  • Josephine, Charlene
  • Bonvento, Gilles
  • Panatier, Aude
  • Lutz, Beat
  • Piazza, Pier Vincenzo
  • Guzmán, Manuel
  • Bellocchio, Luigi
  • Bouzier-Sore, Anne-Karine
  • Grandes, Pedro
  • Bolaños, Juan P.
  • Marsicano, Giovanni
Astrocytes take up glucose from the bloodstream to provide energy to the brain, thereby allowing neuronal activity and behavioural responses1,2,3,4,5. By contrast, astrocytes are under neuronal control through specific neurotransmitter receptors5,6,7. However, whether the activation of astroglial receptors can directly regulate cellular glucose metabolism to eventually modulate behavioural responses is unclear. Here we show that activation of mouse astroglial type-1 cannabinoid receptors associated with mitochondrial membranes (mtCB1) hampers the metabolism of glucose and the production of lactate in the brain, resulting in altered neuronal functions and, in turn, impaired behavioural responses in social interaction assays. Specifically, activation of astroglial mtCB1 receptors reduces the phosphorylation of the mitochondrial complex I subunit NDUFS4, which decreases the stability and activity of complex I. This leads to a reduction in the generation of reactive oxygen species by astrocytes and affects the glycolytic production of lactate through the hypoxia-inducible factor 1 pathway, eventually resulting in neuronal redox stress and impairment of behavioural responses in social interaction assays. Genetic and pharmacological correction of each of these effects abolishes the effect of cannabinoid treatment on the observed behaviour. These findings suggest that mtCB1 receptor signalling can directly regulate astroglial glucose metabolism to fine-tune neuronal activity and behaviour in mice., This work was funded by: INSERM, the European Research Council (Endofood, ERC–2010–StG–260515 and CannaPreg, ERC-2014-PoC-640923, MiCaBra, ERC-2017-AdG-786467), Fondation pour la Recherche Medicale (FRM, DRM20101220445), the Human Frontiers Science Program, Region Nouvelle Aquitaine and Agence Nationale de la Recherche (ANR; NeuroNutriSens ANR-13-BSV4-0006, CaCoVi ANR 18-CE16-0001-02, MitObesity ANR 18-CE14-0029-01, ORUPS ANR-16-CE37-0010-01 and BRAIN ANR-10-LABX-0043) (to G.M.); NIH/NIDA (1R21DA037678-01), Spanish Ministry of Science, Innovation and Universities (MCINU/FEDER; grants SAF2016-78114-R and RED2018-102576-T), Instituto de Salud Carlos III (CB16/10/00282), an EU BATCure grant (666918), Junta de Castilla y León (Escalera de Excelencia CLU-2017-03), Ayudas Equipos Investigación Biomedicina 2017 Fundación BBVA and Fundación Ramón Areces (to J.P.B.); Instituto de Salud Carlos III (PI18/00285; RD16/0019/0018), the European Regional Development Fund, the European Union’s Horizon 2020 Research and Innovation Programme (grant agreement 686009), Junta de Castilla y León (IES007P17) and Fundación Ramón Areces to (A.A.); French State/ANR/IdEx (ANR-10-IDEX-03-02), Eu-Fp7 (FP7-PEOPLE-2013-IEF-623638) and Ramon y Cajal Investigator Program (RYC-2017-21776) (to A.B.-G.); FRM (SPF20121226369) (to R.S.); FRM (ARF20140129235) (to L.B.); Spanish Ministry of Science, Innovation and Universities (MCINU/FEDER; grants SAF2015-64945-R and RTI2018-095311-B-I00) (to M.G.); Canada Research Chair, Alzheimer Society of Canada—Brain Canada (17-09), Natural Sciences and Engineering Research Council (RGPIN-2015-05880), Canadian Breast Cancer Foundation (2015-317342), Canadian Health Research Institute (CIHR, 388808), New Brunswick Innovation Foundation, New Brunswick Health Research Foundation and Université de Moncton (to E.H.-C.); Basque Government (IT1230-19), Red de Trastornos Adictivos, Instituto de Salud Carlos III (ISC-III), European Regional Development Funds-European Union (ERDF-EU; RD16/0017/0012) and MINECO/FEDER, UE (SAF2015-65034-R) (to P.G.); University of the Basque Country PhD contract (PIF 16/251) (to S.A.); POP contract (BES-2016-076766, BES-C-2016-0051) (to I.B.-D.R.); French State/ANR (ANR-10-IDEX and TRAIL ANR-10-LABX-57); French-Swiss ANR-FNS (ANR-15- CE37-0012) (to A.-K.B.-S.); SFB/TRR 58 ‘Fear, anxiety, anxiety disorders’ (subproject A04); and CRC 1193 ‘Neurobiology of resilience’ (subproject B04) (to B.L.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Role of the endocannabinoid system in drug addiction

  • Manzanares, Jorge
  • Cabañero, David
  • Puente, Nagore
  • García-Gutiérrez, María Salud
  • Grandes, Pedro
  • Maldonado, Rafael
Drug addiction is a chronic relapsing disorder that produces a dramatic global health burden worldwide. Not effective treatment of drug addiction is currently available probably due to the difficulties to find an appropriate target to manage this complex disease raising the needs for further identification of novel therapeutic approaches. The endocannabinoid system has been found to play a crucial role in the neurobiological substrate underlying drug addiction. Endocannabinoids and cannabinoid receptors are widely expressed in the main areas of the mesocorticolimbic system that participate in the initiation and maintenance of drug consumption and in the development of compulsion and loss of behavioral control occurring during drug addiction. The identification of the important role played by CB1 cannabinoid receptors in drug addiction encouraged the possible used of an early commercialized CB1 receptor antagonist for treating drug addiction. However, the incidence of serious psychiatric adverse events leaded to the sudden withdrawal from the market of this CB1 antagonist and all the research programs developed by pharmaceutical companies to obtain new CB1 antagonists were stopped. Currently, new research strategies are under development to target the endocannabinoid system for drug addiction avoiding these side effects, which include allosteric negative modulators of CB1 receptors and compounds targeting CB2 receptors. Recent studies showing the potential role of CB2 receptors in the addictive properties of different drugs of abuse have open a promising research opportunity to develop novel possible therapeutic approaches., We acknowledge the financial support of the Spanish MINECO (#SAF2017-84060-R-AEI/FEDER-UE), Instituto de Salud Carlos III-RETICS (##RD16/0017/0020), Ministerio de Sanidad, Servicios Sociales e Igualdad-Plan Nacional Sobre Drogas (#PNSD-2017I068), and the Generalitat de Catalunya-AGAUR ((#2017-SGR-669 and #ICREA Acadèmia2015) and the European Commission-DG RTD (#FP7-HEALTH-F2-2013-602891-NeuroPain) to RM. FEDER funding support is also acknowledged. This work was supported by Red de Trastornos Adictivos, Instituto de Salud Carlos III (ISC-III) and European Regional Development Funds-European Union (ERDF-EU) (RD16/0017/0012), The Basque Government (BCG IT764-13) and MINECO/FEDER, UE (SAF2015-65034-R) to PG. This research was supported by Instituto de Salud Carlos III (RETICS, RD12/0028/0019, RD16/0017/0014 and RD06/0001/1004), Plan Nacional Sobre Drogas (PNSD 2016/016 and 2007/061), Ministerio de Economía y Competitividad (FIS, PI14/00438) and Ministerio de Ciencia e Innovación (SAF2008-01106) to JM., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Role of the endocannabinoid system in drug addiction

  • Manzanares, Jorge
  • Cabañero Ferri, David
  • Puente, Nagore
  • García-Gutiérrez, María S.
  • Grandes, Pedro
  • Maldonado, Rafael, 1961-
Drug addiction is a chronic relapsing disorder that produces a dramaticglobal health burden worldwide. Not effective treatment of drug addiction is currently available probably due to the difficulties to find an appropriate target to manage this complex disease raising the needs for further identification of novel therapeutic approaches. The endocannabinoid system has been found to play a crucial role in the neurobiological substrate underlying drug addiction. Endocannabinoids and cannabinoid receptors are widely expressed in the main areas of the mesocorticolimbic system that participate in the initiation and maintenance of drug consumption and in the development of compulsion and loss of behavioral control occurring during drug addiction. The identification of the important role played by CB1 cannabinoid receptors in drug addiction encouraged the possible used of an early commercialized CB1 receptor antagonist for treating drug addiction. However, the incidence of serious psychiatric adverse events leaded to the sudden withdrawal from the market of this CB1 antagonist and all the research programs developed by pharmaceutical companies to obtain new CB1 antagonists were stopped. Currently, new research strategies are under development to target the endocannabinoid system for drug addiction avoiding these side effects, which include allosteric negative modulators of CB1 receptors and compounds targeting CB2 receptors. Recent studies showing the potential role of CB2 receptors in the addictive properties of different drugs of abuse have open a promising research opportunity to develop novel possible therapeutic approaches., We acknowledge the financial support of the Spanish MINECO (#SAF2017-84060-R-AEI/FEDER-UE), Instituto de Salud Carlos III-RETICS(##RD16/0017/0020), Ministerio de Sanidad, Servicios Sociales e Igualdad-Plan Nacional Sobre Drogas (#PNSD-2017I068), and the Generalitat de Catalunya-AGAUR ((#2017-SGR-669 and #ICREA Acadèmia2015) and the European Commission-DG RTD (#FP7-HEALTH-F2-2013-602891-NeuroPain) to RM. FEDER funding support is also acknowledged. This work was supported by Red de Trastornos Adictivos, Instituto de Salud Carlos III (ISC-III) and European Regional Development Funds-European Union (ERDF-EU) (RD16/0017/0012), The Basque Government (BCG IT764-13) and MINECO/FEDER, UE(SAF2015-65034-R) to PG. This research was supported by Instituto de Salud Carlos III (RETICS, RD12/0028/0019, RD16/0017/0014 and RD06/0001/1004), Plan Nacional Sobre Drogas (PNSD 2016/016 and 2007/061), Ministerio de Economía y Competitividad (FIS, PI14/00438) and Ministerio de Ciencia e Innovación (SAF2008-01106) to JM